Condition
Adult T Cell Leukemia
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Active Not Recruiting1
Terminated1
Clinical Trials (2)
Showing 2 of 2 trials
NCT05377827Phase 1Active Not Recruiting
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
NCT01378871Phase 2TerminatedPrimary
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Showing all 2 trials